Tag: Prescription Drugs

Significant reduction also seen in change from baseline in daily OFF times versus placebo

Findings seen in patients with posterior circulation stroke and with no planned thrombectomy who received alteplase 4.5 to 24 hours after stroke onset

Higher prevalence ratios for misuse, prescription stimulant use disorder seen for those using amphetamines versus methylphenidate

Patients treated with cabozantinib survived significantly longer with no worsening of their disease compared with patients who received placebo

In a recent study, significantly more patients receiving the combination therapy met primary end point of reduction in spleen volume of ≥35 percent from baseline

Withdrawing renin-angiotensin inhibitors/angiotensin receptor-neprilysin inhibitors and mineralocorticoid receptor antagonists tied to higher one-year mortality, morbidity

Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion

Hazard ratio for clinical decline in Clinical Dementia Rating-Sum of Boxes was 0.53 for those treated with gantenerumab the longest

Medication approved for uUTIs in women and pediatric patients aged 12 years and older

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge